Ever expanding rapid diagnostic products

Inverness Medical Innovations develops and manufactures rapid diagnostic products for use in preventive as well as interventional therapies.

Photo: Ever expanding rapid diagnostic products

Information from patients’ body fluids, or tissue, assists physicians to diagnose disease, as well as to measure a patient’s response to a specific therapy. Its range of clinical diagnostic products already includes, the well-known brands Clearview, Inverness Medical TestPack, Binax, Determine, BioStar, and many others. ‘Our high quality immunoassays in pregnancy testing and fertility, respiratory, enteric and infectious diseases, autoimmune disorders, osteoporosis, cancer and cardiology, have demonstrated proven efficiency in clinics, hospitals and laboratories internationally,’ the firm points out.

Currently, Inverness Medical Innovations reports that it is exploring opportunities to optimise the use of its technologies, as well as continually evaluating other technological advances, for development or acquisition, in a variety of medical/health areas.

14.11.2006

More on the subject:

Related articles

Photo

News • Combination of complementary approaches

New dual antiviral strategy against Covid-19 pathogen

A new study proposes a new antiviral strategy against SARS-CoV-2 based on a treatment that combines two complementary approaches, capable of attacking the virus simultaneously.

Photo

Article • Avoiding mistakes in design, equipment, validation, and operation

Laboratory cleaning: Breaking the hidden chain of contamination errors

Microbiological cleanliness in laboratories demands far more than routine disinfection – it requires a comprehensive contamination control strategy from the very first design stage. At the Labs…

Photo

News • Focal cortical dysplasia

Lab-grown mini-brains shed light on childhood epilepsy

Why does the same genetic mutation cause FCDII in some patients but not in others? Researchers developed organoids to model a brain malformation responsible for drug-resistant epilepsy in children.

Subscribe to Newsletter